Clinical Trial Update: A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA) [Phase 2]

View source ↗

Summary

A Phase 2a proof-of-concept trial evaluating Bempikibart (ADX-914) for severe Alopecia Areata is ongoing but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alopecia Areata

Drugs mentioned

• Bempikibart

Snippet

Sponsor: Q32 Bio Inc. | Conditions: Alopecia Areata | Phase 2 | Status: ACTIVE_NOT_RECRUITING